Long-term trends in the burden of leukemia subtypes in China from 1990 to 2021: a Joinpoint regression and age-period-cohort analysis based on GBD 2021 - Top-Institutions - MDSpire

Long-term trends in the burden of leukemia subtypes in China from 1990 to 2021: a Joinpoint regression and age-period-cohort analysis based on GBD 2021

  • By

  • Yudi Shangguan

  • Xinyue Gou

  • Yue Luo

  • Zhuo Chen

  • June 4, 2026

  • 0 min

Share

Top Institutions in Oncology

Brief introduction explaining scope and methodology.

  • #1

    The University of Texas MD Anderson Cancer Center
    The University of Texas MD Anderson Cancer Center

    Houston, Texas

    Key Differentiators

    • Hematology
    • Oncology

  • #2

    Memorial Sloan Kettering Cancer Center
    Memorial Sloan Kettering Cancer Center

    New York, New York

    Key Differentiators

    • Hematology
    • Oncology

  • #3

    Peking University Institute of Hematology
    Peking University Institute of Hematology

    Beijing, China

    Key Differentiators

    • Hematology

  • #4

    Chinese Blood and Marrow Transplantation Registry Group
    Chinese Blood and Marrow Transplantation Registry Group

    Beijing, China

    Key Differentiators

    • Hematology

  • #5

    Swedish Adult Acute Leukemia Registry
    Swedish Adult Acute Leukemia Registry

    Stockholm, Sweden

    Key Differentiators

    • Hematology

Original Source(s)

Long-term trends in the burden of leukemia subtypes in China from 1990 to 2021: a Joinpoint regression and age-period-cohort analysis based on GBD 2021

  • by Yudi Shangguan, Xinyue Gou, Yue Luo, Zhuo Chen

  • June 4, 2026

Related Content

Emil J Freireich and Baruch Spinoza: birds of a feather?

HSP90 inhibitor NVP-BEP800 affects stability of SRC kinases and growth of T-cell and B-cell acute lymphoblastic leukemias

Dana-Farber Cancer Institute and Dana-Farber/Boston Children’s Cancer and Blood Disorders Center recognized for exceptional outcomes in donor stem cell transplants

Dana-Farber Cancer Institute’s adult stem cell transplant program and Dana-Farber/Boston Children’s Cancer and Blood Disorders Center’s pediatric stem cell transplant program have once again received exceptional ratings from the Center for International Blood & Marrow Transplant Research (CIBMTR), earning a +1 performance score, the highest possible designation, on their annual center-specific survival reports.

  • December 17, 2025

  • 4 min